Intravitreal Avastin for choroidal neovascularisation in pathological myopia: the controversy continues
نویسندگان
چکیده
منابع مشابه
Intravitreal bevacizumab (Avastin) for choroidal neovascularisation secondary to pathological myopia: 6-month results.
BACKGROUND To determine the efficacy and safety of intravitreal Avastin (bevacizumab) in the treatment of choroidal neovascularisation (CNV) secondary to pathological myopia (PM). METHODS This paper reports on a consecutive prospective study of patients with CNV secondary to PM who were treated with intravitreal bevacizumab (1.25 mg/0.05 ml). Patients underwent complete ophthalmic evaluation,...
متن کاملLong-term results of intravitreal bevacizumab for choroidal neovascularisation in pathological myopia.
AIM To evaluate the long-term results and prognostic factors of intravitreal bevacizumab (IVB) for myopic choroidal neovascularisation (mCNV). METHODS Thirty-two eyes of 30 patients with mCNV were included in a prospective case series. Treatment consisted of three monthly 1.25 mg IVB injections. Best corrected visual acuity (BCVA) and CNV area were compared before and after treatment. Prognos...
متن کاملIntravitreal anti-VEGF therapy for choroidal neovascularisation secondary to pathological myopia: 4-year outcome.
OBJECTIVE To report the visual outcome after 4-year follow-up in a series of highly myopic eyes with choroidal neovascularisation (CNV) treated with antivascular endothelial growth factor (anti-VEGF) drugs. METHODS A retrospective, non-randomised, multicentre, consecutive, interventional case series study was performed. 92 highly myopic eyes with subfoveal CNV were treated with intravitreal i...
متن کاملChoroidal neovascularisation in pathological myopia: an update in management.
Choroidal neovascularisation (CNV) secondary to pathological myopia is an important cause of significant visual impairment in young and middle aged adults globally and is particularly prevalent in Asian populations. In the past few years, there have been rapid advancements in the different treatments for myopic CNV. The purpose of this perspective is to give an overview of the natural history o...
متن کاملBevacizumab suppresses choroidal neovascularisation caused by pathological myopia.
Bevacizumab (Avastin, Genentech) is a recombinant humanised, full length, antiVEGF monoclonal antibody that binds all isoforms of VEGF-A. It has been shown to prolong survival of patients with advanced colon cancer when combined with 5-fluorouracil. In this report, we describe the effect of bevacizumab in two patients with choroidal neovascularisation (CNV) secondary to pathological myopia, whi...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: British Journal of Ophthalmology
سال: 2007
ISSN: 0007-1161
DOI: 10.1136/bjo.2006.101337